Aclarion Secures Patent #12,601,803 to Expand IP to 64 Patents, Drive AI-Based Scaling
Aclarion received U.S. Patent #12,601,803 for its Nociscan platform’s machine learning–driven MRS analysis, boosting its IP portfolio to 64 patents and protecting AI-based biomarker extraction and quality control. It underpins scalable automation, potential gross margin expansion and broader clinical adoption in the 266 million-person chronic low back pain market.
1. Patent Details and Scope
Aclarion’s U.S. Patent #12,601,803 covers its machine learning–based system for training models on MRS spectral data and predicting pain-related biomarkers, including AI-driven automated data quality controls that exclude low-quality signals such as excessive lipids or low signal-to-noise ratio.
2. Platform Scaling and Gross Margins
The patent protects AI-driven automation within Nociscan workflows, enabling accelerated report generation and reduced manual quality reviews, which underpins the company’s ability to scale operations efficiently and drive strong gross margin expansion.
3. IP Portfolio Expansion
With the issuance of this patent, Aclarion’s intellectual property portfolio expands to 64 issued and pending patents worldwide, reinforcing its competitive moat in the AI-driven healthcare diagnostics sector.
4. Market Opportunity
Aclarion addresses a global chronic low back pain market of approximately 266 million people, where Nociscan’s clinically actionable biomarker insights have demonstrated up to a 97% surgical success rate when positive discs are treated.